Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Active not recruiting 4Completed 1

Sponsor Class

OTHER 10NETWORK 8NIH 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Plasma cell 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Carcinoma, Renal Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NIH × Has results × Watchful Waiting × Clear all
NCT03055013 2026-06-03

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

National Cancer Institute (NCI)

Phase 3 Active not recruiting
819 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT01251861 2026-05-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
108 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT02275533 2026-05-28

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
82 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

NCT00093470 2024-03-20

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

National Cancer Institute (NCI)

Phase 3 Completed
144 enrolled 8 charts
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡